Morgan Stanley’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-576,319
| Closed | -$5.17M | – | 6745 |
|
|
2016
Q3 | $5.17M | Buy |
576,319
+570,564
| +9,914% | +$4.06M | ﹤0.01% | 2625 |
|
|
2016
Q2 | $31K | Sell |
5,755
-14,993
| -72% | -$76.9K | ﹤0.01% | 5701 |
|
|
2016
Q1 | $96K | Sell |
20,748
-130,168
| -86% | -$523K | ﹤0.01% | 5336 |
|
|
2015
Q4 | $784K | Buy |
150,916
+22,335
| +17% | +$130K | ﹤0.01% | 4225 |
|
|
2015
Q3 | $778K | Sell |
128,581
-97,613
| -43% | -$1.2M | ﹤0.01% | 4315 |
|
|
2015
Q2 | $3.57M | Buy |
226,194
+73,328
| +48% | +$891K | ﹤0.01% | 3096 |
|
|
2015
Q1 | $1.66M | Buy |
152,866
+31,926
| +26% | +$326K | ﹤0.01% | 3747 |
|
|
2014
Q4 | $1.27M | Sell |
120,940
-102,455
| -46% | -$1M | ﹤0.01% | 3955 |
|
|
2014
Q3 | $2.14M | Sell |
223,395
-77,884
| -26% | -$795K | ﹤0.01% | 3379 |
|
|
2014
Q2 | $3.48M | Buy |
301,279
+146,411
| +95% | +$1.33M | ﹤0.01% | 3009 |
|
|
2014
Q1 | $1.55M | Buy |
154,868
+129,439
| +509% | +$1.87M | ﹤0.01% | 3642 |
|
|
2013
Q4 | $332K | Buy |
25,429
+3,363
| +15% | +$46.3K | ﹤0.01% | 4759 |
|
|
2013
Q3 | $329K | Buy |
22,066
+7,391
| +50% | +$88.6K | ﹤0.01% | 4609 |
|
|
2013
Q2 | $137K | Buy |
+14,675
| New | +$99.4K | ﹤0.01% | 4992 |
|
Morgan Stanley's RPTP Position: Q4 2016 in Review
Morgan Stanley sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 576,319 shares — an estimated $5.17M sold.
Morgan Stanley first reported a position in RPTP in Q2 2013 and held it in 14 quarters. The position peaked at $5.17M in Q3 2016. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.
- Morgan Stanley reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
- Morgan Stanley sold 576,319 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $5.17M.
- Morgan Stanley first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 14 quarters.
- Morgan Stanley's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $5.17M in Q3 2016.
- 0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.
Based on Morgan Stanley's 13F filing for Q4 2016, filed 13 Feb 2017.